Alzheimer's β-Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor

The amyloid-beta (Abeta) peptide is neurotoxic and associated with the pathology of Alzheimer's disease (AD). We investigated the effect of Abeta peptides on insulin binding to the insulin receptor because it is known that (1) Abeta and insulin are both amyloidogenic peptides sharing a common sequence recognition motif, (2) Abeta and insulin are substrates for the same insulin degrading enzyme, and (3) impaired glucose metabolism is a characteristic event in the pathology of AD. We discovered that Abeta(1-40) and Abeta(1-42,) the main physiological forms, reduced insulin binding and receptor autophosphorylation. The reduction in binding was caused by a decrease in the affinity of insulin binding to the insulin receptor. This reduction was independent of the receptor concentration. The reverse, control peptide Abeta(40-1) did not reduce insulin binding or insulin receptor autophosphorylation. These results demonstrate that Abeta is a direct competitive inhibitor of insulin binding and action. We speculate that the increased levels of Abeta in Alzheimer's disease may be linked to the associated insulin resistance that has been observed previously in this disease.

[1]  I. Kurochkin.  Amyloidogenic determinant as a substrate recognition motif of insulin‐degrading enzyme , 1998, FEBS letters.

[2]  M. Racchi,et al.  Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase‐dependent pathway , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  J. Newcomer,et al.  Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. , 1999, Archives of general psychiatry.

[4]  Johanna Kuusisto,et al.  Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study , 1997, BMJ.

[5]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[6]  M. Mattson,et al.  Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. , 1997, Journal of neurochemistry.

[7]  O Almkvist,et al.  Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment , 2001, Neuroreport.

[8]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[9]  G. Zuliani,et al.  Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. , 1999, Dementia and geriatric cognitive disorders.

[10]  E. Van Obberghen,et al.  Phosphorylation of the hepatic insulin receptor , 1982, FEBS letters.

[11]  G. Wilcock,et al.  Hyperinsulinaemia and Alzheimer's disease. , 1994, Age and ageing.

[12]  R. Martins,et al.  The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-beta Levels: Resolubilization of amyloid-beta with transition metal ion chelators. , 2001, Journal of Alzheimer's disease : JAD.

[13]  M. Mattson,et al.  Impairment of Glucose and Glutamate Transport and Induction of Mitochondrial Oxidative Stress and Dysfunction in Synaptosomes by Amyloid β‐Peptide: Role of the Lipid Peroxidation Product 4‐Hydroxynonenal , 1997, Journal of neurochemistry.

[14]  H. Langen,et al.  Rat Brain Glyceraldehyde‐3‐Phosphate Dehydrogenase Interacts with the Recombinant Cytoplasmic Domain of Alzheimer's β‐Amyloid Precursor Protein , 1993, Journal of neurochemistry.

[15]  W. Meier-Ruge,et al.  The Significance of Glucose Turnover in the Brain in the Pathogenetic Mechanisms of Alzheimer's Disease , 1996, Reviews in the neurosciences.

[16]  J. Cresto,et al.  Degradation of Soluble Amyloid β-Peptides 1–40, 1–42, and the Dutch Variant 1–40Q by Insulin Degrading Enzyme from Alzheimer Disease and Control Brains , 2000, Neurochemical Research.

[17]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Binetti,et al.  Energy metabolism inhibition impairs amyloid precursor protein secretion from Alzheimer's fibroblasts , 1999, Neuroscience Letters.

[19]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.

[20]  T. Iwatsubo,et al.  Cerebrospinal fluid levels of amyloid β-peptide1–42, but not tau have positive correlation with brain glucose metabolism in humans , 1999, Neuroscience Letters.

[21]  J T Finch,et al.  Binding of the dye congo red to the amyloid protein pig insulin reveals a novel homology amongst amyloid-forming peptide sequences. , 1992, Journal of molecular biology.

[22]  E. Helmerhorst,et al.  Purification of A14-tyrosyl [125I]iodoinsulin using C18 reverse-phase cartridges. , 1992, Analytical biochemistry.

[23]  D. Selkoe,et al.  Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme , 2000, The Journal of Neuroscience.

[24]  B. Posner,et al.  Insulin-degrading enzyme. , 1996, Clinical and investigative medicine. Medecine clinique et experimentale.

[25]  A. Ott.  Risk of dementia: The Rotterdam Study , 1997 .

[26]  K. Akiyama,et al.  Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type , 1991, Biological Psychiatry.

[27]  S. Hoyer.  Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases. , 1992, Molecular and chemical neuropathology.

[28]  V. Bigl,et al.  Altered phosphofructokinase mRNA levels but unchanged isoenzyme pattern in brains from patients with Alzheimer's disease. , 2000, Brain research. Molecular brain research.

[29]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Sutcliffe,et al.  Examination of different preparations of human placental plasma membrane for the binding of insulin, transferrin and immunoglobulins. , 1981, Journal of reproduction and fertility.

[31]  K. Eschrich,et al.  Interaction of rat brain phosphofructokinase with Alzheimer's βA4-amyloid , 1995, Neurochemistry International.

[32]  B. Sommer,et al.  Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. , 2000, Nature neuroscience.

[33]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[34]  N L Foster,et al.  Discordance between Traditional Pathologic and Energy Metabolic Changes in Very Early Alzheimer's Disease: Pathophysiological Implications , 1999, Annals of the New York Academy of Sciences.

[35]  R. Black,et al.  Expression of 'Alzheimer antigens' in cultured skin fibroblasts. , 1991, Archives of neurology.

[36]  D. Schubert,et al.  Amyloid beta-protein activates tachykinin receptors and inositol trisphosphate accumulation by synergy with glutamate. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Eschrich,et al.  Interaction of rat brain phosphofructokinase with Alzheimer's beta A4-amyloid. , 1995, Neurochemistry international.

[38]  S. Estus,et al.  Aggregated Amyloid-β Protein Induces Cortical Neuronal Apoptosis and Concomitant “Apoptotic” Pattern of Gene Induction , 1997, The Journal of Neuroscience.

[39]  D. Morgan,et al.  Purification and characterization of the human brain insulin receptor. , 1986, The Journal of biological chemistry.

[40]  I. Kurochkin,et al.  Alzheimer's β‐amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme , 1994, FEBS letters.

[41]  C. Masters,et al.  Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion* , 1999, The Journal of Biological Chemistry.

[42]  C. Yip.  The insulin‐binding domain of insulin receptor is encoded by exon 2 and exon 3 , 1992, Journal of cellular biochemistry.

[43]  L. Kiessling,et al.  Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. , 1999, Biochemistry.

[44]  M. Mattson,et al.  Amyloid β‐Peptide Induces Cell Monolayer Albumin Permeability, Impairs Glucose Transport, and Induces Apoptosis in Vascular Endothelial Cells , 1997 .

[45]  K. Jellinger,et al.  Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.